OncoMatch/Clinical Trials/NCT06203210
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Is NCT06203210 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Ifinatamab deruxtecan and Topotecan for small cell lung cancer.
Treatment: Ifinatamab deruxtecan · Topotecan · Amrubicin · Lurbinectedin — This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
extensive-stage small cell lung cancer (ES-SCLC)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — systemic therapy for SCLC
Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval of ≥30 days.
Cannot have received: B7-H3 targeted agent (orlotamab, enoblituzumab, I-DXd)
Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd.
Cannot have received: antibody drug conjugate (ADC) with exatecan derivative (trastuzumab deruxtecan)
Exception: if discontinued due to treatment-related toxicities
Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
Cannot have received: topoisomerase I inhibitor
Has received any of the comparators used in this study or any topoisomerase I inhibitor.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Highlands Oncology Group · Springdale, Arkansas
- Clinical Research Providence Medical Foundation · Fullerton, California
- UCLA Hematology-Oncology · Los Angeles, California
- UCSF Mission Bay Mission Hall · San Francisco, California
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06203210 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7-H3 targeted agent, antibody drug conjugate (ADC) with exatecan derivative, topoisomerase I inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages